Compare Stocks

→ What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$1.45 -2.0%	$1.85	$1.10 ▼ $5.90	$119.15M	1.94	1.14 million shs	452,774 shs
CYTT Cyteir Therapeutics	$3.01 -0.3%	$3.01	$1.65 ▼ $3.19	$108.35M	0.08	N/A	551,300 shs
PMVP PMV Pharmaceuticals	$1.82 +1.7%	$1.84	$1.18 ▼ $9.72	$93.63M	1.56	474,356 shs	457,060 shs
RLMD Relmada Therapeutics	$3.00 -1.3%	$3.94	$2.36 ▼ $7.22	$90.52M	0.27	79,927 shs	63,626 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	-2.68%	+2.84%	-39.58%	-73.54%
CYTT Cyteir Therapeutics	0.00%	0.00%	0.00%	+300,999,900.00%	+300,999,900.00%
PMVP PMV Pharmaceuticals	0.00%	-10.78%	-2.67%	-2.93%	-65.98%
RLMD Relmada Therapeutics	0.00%	-1.64%	-19.35%	-55.88%	+5.63%

Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)

In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.

You just have to make this simple move before July 30, 2024.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACET Adicet Bio	2.4789 of 5 stars	3.4	3.0	0.0	0.0	2.7	2.5	0.6
CYTT Cyteir Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	2.37 of 5 stars	3.6	3.0	0.0	0.0	2.5	1.7	0.6
RLMD Relmada Therapeutics	2.602 of 5 stars	2.0	1.0	0.0	4.4	2.5	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.71	Moderate Buy	$14.20	879.31% Upside
CYTT Cyteir Therapeutics	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	3.20	Buy	$5.75	215.93% Upside
RLMD Relmada Therapeutics	N/A	N/A	$25.00	733.33% Upside

Current Analyst Ratings

Latest ACET, RLMD, PMVP, and CYTT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2024	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2024	ACET Adicet Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
5/15/2024	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/14/2024	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/13/2024	PMVP PMV Pharmaceuticals	CLSA Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2024	PMVP PMV Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/23/2024	ACET Adicet Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
4/12/2024	PMVP PMV Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
4/2/2024	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/20/2024	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/20/2024	ACET Adicet Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00

(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	$24.99M	4.77	N/A	N/A	$3.15 per share	0.46
CYTT Cyteir Therapeutics	N/A	N/A	N/A	N/A	$4.13 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$4.13 per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$2.39 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$142.66M	-$2.95	N/A	N/A	N/A	N/A	-55.79%	-47.60%	8/14/2024 (Estimated)
CYTT Cyteir Therapeutics	-$46.06M	-$0.94	N/A	∞	N/A	N/A	-24.88%	-23.83%	N/A
PMVP PMV Pharmaceuticals	-$68.96M	-$1.33	N/A	N/A	N/A	N/A	-29.14%	-26.24%	8/14/2024 (Estimated)
RLMD Relmada Therapeutics	-$98.79M	-$3.13	N/A	N/A	N/A	N/A	-102.09%	-91.30%	8/13/2024 (Estimated)

Latest ACET, RLMD, PMVP, and CYTT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2024	Q1 2024	PMVP PMV Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	N/A	N/A
5/8/2024	Q1 2024	RLMD Relmada Therapeutics	-$0.90	-$0.72	+$0.18	-$0.72	N/A	N/A
3/19/2024	Q4 2023	ACET Adicet Bio	-$0.72	-$0.69	+$0.03	-$0.69	$5.00 million	N/A
3/19/2024	Q4 2023	RLMD Relmada Therapeutics	-$0.88	-$0.84	+$0.04	-$0.84	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	N/A	N/A	N/A	N/A	N/A
CYTT Cyteir Therapeutics	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	N/A	14.34	14.34
CYTT Cyteir Therapeutics	N/A	21.89	21.89
PMVP PMV Pharmaceuticals	N/A	16.79	16.79
RLMD Relmada Therapeutics	N/A	6.82	6.82

Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
CYTT Cyteir Therapeutics	63.24%
PMVP PMV Pharmaceuticals	90.20%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	19.10%
CYTT Cyteir Therapeutics	14.40%
PMVP PMV Pharmaceuticals	7.60%
RLMD Relmada Therapeutics	18.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	143	82.17 million	66.48 million	Optionable
CYTT Cyteir Therapeutics	46	36.00 million	30.81 million	N/A
PMVP PMV Pharmaceuticals	63	51.44 million	47.53 million	Optionable
RLMD Relmada Therapeutics	20	30.17 million	24.74 million	Optionable

ACET, RLMD, PMVP, and CYTT Headlines

Recent News About These Companies

May 31 at 6:45 PM | accesswire.com

INVESTIGATION PROGRESS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 30 at 2:00 PM | accesswire.com

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 28, 2024 | investorplace.com

7 Penny Biotech Stocks to Triple Your Investment

May 27, 2024 | finance.yahoo.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript

May 19, 2024 | accesswire.com

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 17, 2024 | accesswire.com

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 16, 2024 | accesswire.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 15, 2024 | accesswire.com

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Relmada Therapeutics on Strong Clinical Trials and Financial Footing

May 10, 2024 | markets.businessinsider.com

Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability

May 9, 2024 | finance.yahoo.com

Q1 2024 Relmada Therapeutics Inc Earnings Call

May 8, 2024 | msn.com

RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024

May 8, 2024 | prnewswire.com

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 7, 2024 | marketbeat.com

Relmada Therapeutics (RLMD) Set to Announce Quarterly Earnings on Wednesday

May 6, 2024 | prnewswire.com

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

April 16, 2024 | finance.yahoo.com

RELMADA THERAPEUT.DL-,001 (4E2.F)

March 21, 2024 | seekingalpha.com

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

March 21, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial Stability

March 20, 2024 | finance.yahoo.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript

March 20, 2024 | finanznachrichten.de

Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 20, 2024 | finance.yahoo.com

Q4 2023 Relmada Therapeutics Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adicet Bio

NASDAQ:ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Cyteir Therapeutics

NASDAQ:CYTT

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

PMV Pharmaceuticals

NASDAQ:PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Relmada Therapeutics

NASDAQ:RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial